Evidence for improvements to risk stratification in high-risk gastrointestinal stromal tumor patients
Alessandra Greco(St. Catherine University), Marco Massani(AULSS 2 Marca Trevigiana), Cesare Ruffolo(Ca' Foncello Hospital), Sabrina Rossi(Ca' Foncello Hospital), Giovanni Morana(Ca' Foncello Hospital), Bruno Pauletti(AULSS 2 Marca Trevigiana), Angelo Paolo Dei Tos(University of Padua)
Cited by 2
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k